Understanding TreatmentOptions in
Cutaneous Lymphoma
32
References
33
ShareYour Story
Sharing your story is a fantasticway for you tohelp otherswho are traveling
down the same path that you are—whether you are a patient, caregiver,
healthcare provider, or a familymember or friend.Patients and otherswho read
our newsletter or visit ourwebsite often tell us that one of their favorite features
are the stories of the lives of peoplewho are affected by cutaneous lymphoma.
Contact us at
or 248.644.9014 if youwould like to share
your story.
BecomeanAdvocate
Becoming an advocate for people affected by cutaneous lymphoma is a very
important way that you can become involved in supporting patientswith
cutaneous lymphoma.You canparticipate by visiting theAdvocacy section of
ourwebsite at
tomonitor advocacy news and
action alerts that you canparticipate in.We also invite you to contact us at
or 248.644.9014 if you are interested in our advocacy
efforts.
Volunteer
At theCutaneousLymphomaFoundation,we have specific projects or
tasks that arise forwhichwe need volunteer help. If you are interested in
volunteering, send us an email at
formore information
or call 248.644.9014.
Learnmore about how you can get involved and give back.Visit the
GET INVOLVED andWAYSTOGIVE sections of ourwebsite at
1. WillemzeR, JaffeES,BurgG, et al.WHO-EORTC classification for
cutaneous lymphomas.
Blood
. 2005;105(10):3768-3785.
2. OlsenE,VonderheidE,PimpinelliN, et al.Revisions to the staging and
classification ofmycosis fungoides andSezary syndrome: a proposal of the
International Society forCutaneousLymphomas (ISCL) and the cutaneous
lymphoma task force of theEuropeanOrganization of Research and
Treatment ofCancer (EORTC).
Blood
. 2007;110(6):1713-1722.
3. LansiganF, Foss FM.Current and emerging treatment strategies for
cutaneousT-cell lymphoma.
Drugs
. 2010;70(3):273-286.
4. BloomT,KuzelTM,QuerfeldC,Guitart J,RosenST.CutaneousT-cell
lymphomas: a review of newdiscoveries and treatments.
CurrTreatOptions
Oncol
. 2012;13(1):102-121.
5. National ComprehensiveCancerNetwork.NCCNClinical Practice
Guidelines inOncology:NHL (Mycosis Fungoides andSézary Syndrome).
2013.
6. DuvicM,ApisarnthanaraxN,CohenDS, SmithTL,HaCS,Kurzrock
R.Analysis of long-term outcomes of combinedmodality therapy for
cutaneousT-cell lymphoma.
JAmAcadDermatol
. 2003;49(1):35-49.
7. Whittaker S,OrtizP,DummerR, et al.Efficacy and safety of bexarotene
combinedwithpsoralen-ultravioletA (PUVA) comparedwithPUVA
treatment alone in stage IB-IIAmycosis fungoides: final results from the
EORTCCutaneousLymphomaTaskForce phase III randomized clinical
trial (NCT00056056).
Br JDermatol
. 2012;167(3):678-687.
8. ZackheimHS,Kashani-SabetM,AminS.Topical corticosteroids for
mycosis fungoides.Experience in 79 patients.
ArchDermatol
.
1998;134(8):949-954.
9. ZackheimHS.Treatment of patch-stagemycosis fungoideswith topical
corticosteroids.
DermatolTher
. 2003;16(4):283-287.
10. ZackheimHS.Topical carmustine (BCNU) in the treatment ofmycosis
fungoides.
DermatolTher
. 2003;16(4):299-302.
11. LessinSR,DuvicM,Guitart J, et al.Topical chemotherapy in cutaneous
T-cell lymphoma: positive results of a randomized, controlled,multicenter
trial testing the efficacy and safety of a novelmechlorethamine, 0.02%, gel
inmycosis fungoides.
JAMADermatol
. 2013;149(1):25-32.
REFERENCES
